 SOUTH SAN FRANCISCO, Calif., June 01, 2021 GLOBE NEWSWIRE -- Day One Biopharmaceuticals, Inc. Nasdaq: DAWN, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the closing of its initial public offering of 11,500,000 shares of its common stock, including the full exercise of the underwriters option to purchase up to 1,500,000 additional shares of common stock, at a public offering price of 16.00 per share. All of the shares were offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, were 184.0 million. The shares began trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol DAWN. 